Question normal

Underserved populations suffer from lack of patient-provider engagement, resulting in decreased effectiveness of medical interventions. To overcome disparities for both common and niche disease states, Epharmix develops and clinically validates tailored "digital interventions:" simple communication tools that increase adherence and education, and assist with data collection. Patient outcomes improve, resulting in substantial financial gains for payers and thus aligning incentives for patient/provider/payer.
Example: a post-surgical patient may develop a hospital-acquired infection. With the Epharmix-designed product "EpxWound," the patient is prompted to monitor and communicate any potentially negative developments, and if necessary the relevant nurse or doctor is automatically made aware of the changes.
Epharmix, a funded startup, currently has dozens of interventions built and at varying stages of clinical validation, and has full-time clinical, engineering, and sales team members.